Vaxart Q2 Earnings Call Highlights

Key Points

• Interested successful Vaxart, Inc.? Here are 5 stocks we similar better.

• Vaxart reported favorable 12-month information data from its 400-person Phase II-B COVID-19 vaccine sentinel cohort, with nary vaccine-related superior complications. The larger, astir 5,000-participant cohort is afloat enrolled, with top-line information expected successful the archetypal fractional of 2027, pending BARDA approval.

• BARDA provided $29 million to money expanded safety, immunogenicity and efficacy analyses, including mucosal antibody testing, cellular biomarkers and genomic sequencing crossed the main survey cohort.

• Vaxart ended Q2 2026 with $64 cardinal successful currency and short-term investments, capable to money operations into Q2 2027 nether its existent plan. The institution is inactive seeking a norovirus vaccine spouse and has revised committee enactment and committee structures pursuing a shareholder practice agreement.

• 3 Stocks Under $5 With Strong Analyst Upside Potential

Vaxart (OTCMKTS:VXRT) said it has reported affirmative 12-month information information from the 400-participant Sentinel cohort of its Phase II-B COVID-19 vaccine proceedings and remains connected way to disclose top-line information from the larger, astir 5,000-participant main cohort successful the archetypal fractional of 2027.

The institution discussed the objective update, fiscal position, concern efforts and governance changes during a stockholder fireside chat. Vaxart's Phase II-B COVID-19 survey is funded done the Biomedical Advanced Research and Development Authority's, oregon BARDA's, Project NextGen initiative.

Sentinel Cohort Shows Favorable Safety Profile

→ No Hangover: Revisiting Microsoft One Week After Earnings

Chief Medical Officer Dr. James F. Cummings said the Sentinel cohort was designed chiefly to measure information earlier enlargement into the larger survey population. In the cohort, 201 participants received Vaxart's oral COVID-19 vaccine campaigner targeting the XBB variant, portion 199 received an approved injectable mRNA vaccine comparator.

According to Cummings, determination were nary vaccine-related superior wellness complications and nary terrible oregon long-lasting adverse events successful either radical implicit the 12-month period.

→ MarketBeat Week successful Review – 08/03 - 08/07

The astir commonly reported broadside effects among oral-vaccine recipients were mild-to-moderate fatigue, reported by 20.9% of participants; headache, reported by 18.9%; and nonaccomplishment of appetite, reported by astir 10%. Fewer than 10% of oral-vaccine recipients reported different broadside effects, helium said.

Among mRNA vaccine recipients, much than 60% reported injection-site pain, portion 40.2% reported injection-site tenderness. Other reported broadside effects included fatigue successful 35.2% of participants, musculus symptom successful 33.2%, and headache successful 28.6%. Cummings said betwixt 10% and 15% of mRNA recipients reported associated pain, chills, nausea, diarrhea and limb swelling.